SARS-CoV-2 spike therapeutic antibodies in the age of variants.

Baum, Alina; Kyratsous, Christos A

Baum, Alina; Kyratsous, Christos A.

Baum A; Regeneron Pharmaceuticals Inc., Tarrytown, NY.
Kyratsous CA; Regeneron Pharmaceuticals Inc., Tarrytown, NY.

J Exp Med ; 218(5)2021 05 03.

Article in English | MEDLINE | ID: covidwho-1387678

ABSTRACT

ABSTRACT

Christos Kyratsous, Vice President of Research, Infectious Diseases, and Viral Vector Technologies at Regeneron Pharmaceuticals, and Alina Baum, Associate Director, Infectious Diseases Associate at Regeneron Pharmaceuticals, discuss the development of antibody therapeutics targeting the spike protein of SARS-CoV-2.

Subject(s)

Aging/immunology; Antibodies, Viral; COVID-19/immunology; COVID-19/therapy; SARS-CoV-2/immunology; Spike Glycoprotein, Coronavirus/immunology; Antibodies, Viral/immunology; Antibodies, Viral/therapeutic use; Humans; Immunization, Passive; COVID-19 Serotherapy

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Aging / Spike Glycoprotein, Coronavirus / SARS-CoV-2 / COVID-19 / Antibodies, Viral Topics: Variants Limits: Humans Language: English Year: 2021 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google